27 results about "Fluoxetine" patented technology

The application provides an application of a motion-induced sweat extract in preparation of a medicine for treating, relieving or preventing depression and / or anxiety, and belongs to the field of biological medicine. Specifically, sweat is induced by making a healthy subject perform aerobic exercise of a specific intensity (such as 60%-80% of maximum heart rate), the sweat is collected and eluted by physiological saline, centrifuged and filtered to obtain a biologically active sweat extract. The extract is analyzed by transcriptomics and reverse transcription method to predict the anti-depression potential, and it is proved by in-vivo animal experiments that the extract can significantly improve the anhedonia, behavioral despair and anxiety-like behavior of a depression model mouse, and the effect of a high dose is equivalent to that of a first-line drug fluoxetine. The preparation raw material provided by the application is natural and safe, the preparation process is simple and the cost is low, and a new, easy-to-promote alternative strategy is provided for the prevention and treatment of depression.

The present invention provides a pharmaceutical composition comprising dextromethorphan, the composition comprising dextromethorphan or a pharmaceutically acceptable salt thereof, and fluoxetine or a pharmaceutically acceptable salt thereof. According to the pharmaceutical composition provided by the invention, the dextromethorphan or the pharmaceutically acceptable salt of the dextromethorphan and the fluoxetine or the pharmaceutically acceptable salt of the fluoxetine are combined according to a specific proportion, so that the pharmaceutical composition not only has an excellent synergistic effect, but also reduces the dosage of the dextromethorphan and the fluoxetine which are independently used. The invention also provides application of the pharmaceutical composition in preparation of drugs for preventing and / or treating cough and neuropsychiatric disorders, especially depression.

The application belongs to the technical field of medicines, and specifically discloses an anti-depression m-hydroxybenzoic acid compound and a preparation method and application thereof; the m-hydroxybenzoic acid compound Hyperioxides A-F provided by the application has not been reported; the six compounds have good anti-depression effects, and further research shows that the compounds Hyperioxide A, Hyperioxide D, Hyperioxide E and Hyperioxide F have significant protective effects on SH-SY5Y cells induced by corticosterone, and are superior to positive drugs fluoxetine and Luoyoutei, and can be used for developing drugs for treating depression.

The invention belongs to the technical field of biological medicines, and particularly relates to a group of synergists for anti-tuberculosis infection medicines and application of the synergists. In the invention, Vortioxetine (Vor) shows obvious activity for enhancing mycobacterium infection resistance: under the concentration of 2 mu g / mL, the MIC (minimal inhibitory concentration) of Bedaquiline to H37Rv can be reduced by about 64 times (from 0.06 mu g / mL to 0.0009375 mu g / mL), and the MIC of Bedaquiline to an Rv0678 mutant strain can be reduced by about 64 times (from 1 mu g / mL to 0.0156 mu g / mL). And the content of sertraline hydrochloride (STL) can be reduced by about 16 times and 8 times respectively. The synergistic effect of fluoxetine (FXT) is weakest and is only reduced by two times. The synergist disclosed by the invention is a drug which has been sold on the market, so that the synergist has safety and complete medication guidance. The preparation process and the production process are both perfect, the product can be quickly sold on the market, the selling price is reasonable, the market acceptability is good, and the patient compliance is high. The votioxetine or the sertraline can be used as a synergist of a medicine for resisting mycobacterium tuberculosis infection.

The application discloses a lycoctine type diterpenoid alkaloid compound and a preparation method and application thereof. 20 The diterpenoid alkaloid compound Carmaloidline E shows significant antidepressant activity in a mouse behavioral despair model experiment, is obviously superior to fluoxetine as a positive medicine, and can be used for developing antidepressant drugs.

The invention discloses application of Cacumen biotae-derived extracellular vesicles in preparation of drugs for treating anxiety, depression or insomnia. The EVs are separated and purified from cacumen biotae through a specific differential ultracentrifugation method, the EVs have a typical double-layer membrane structure, the average particle size is about 100 nm, about 1012 EVs can be extracted from each gram of cacumen biotae, and 62 volatile components are contained. Cacumen biotae EVs can be taken by PC12 cells, and corticosterone-induced neuron damage can be relieved; for chronic constraint stress model mice, anxiety behaviors and spatial learning and memory disorders can be improved, and central nervous inflammation can be inhibited; for chronic unpredictable mild stress model mice, the weight, the sucrose preference rate and the cognitive ability can be recovered, and the levels of 5-hydroxytryptamine and gamma-aminobutyric acid are increased; and for 4-chloro-DL-phenylalanine induced insomnia model mice, the sleep condition can be improved, the neurotransmitter level can be recovered, and the effect is equivalent to that of positive drugs such as citalopram, fluoxetine, diazepam and the like.

The invention provides a lipidosome preparation capable of performing brain-targeted drug delivery in a depression model, a preparation method of the lipidosome preparation and application of the lipidosome preparation in improving the anti-depression effect of fluoxetine, and belongs to the technical field of pharmaceutical preparations. The composition disclosed by the invention consists of DOPG, DSPE-PEG2000-PGP, DSPE-PEG2000, cholesterol, fluoxetine and celecoxib, and can be used for improving the anti-depression effect of fluoxetine. The double-drug-loading liposome with high entrapment efficiency and uniform particle size is prepared through a film hydration-film extrusion method, has good stability and biocompatibility, has an obvious targeting drug delivery effect in a chronic social contusion stress model, is suitable for a combined treatment strategy of depression, and has a good clinical application prospect.

The invention discloses application of enterobacter murine in preparation of a medicine for preventing or treating depression, and belongs to the field of medicine. The invention relates to an application of enterobacter murine in preparation of a medicine for preventing or treating depression. According to the present invention, the enterobacter muricatum is Muriaculum gardrongarter, and is preserved in the German Microbiological Culture Collection Center, and the preservation number is DSM 108194. The enterobacter muricatum can be used for preparing the enterobacter muricatum, the invention discloses application of active enterobacter murine, namely application of the active enterobacter murine in preparation of drugs for preventing or treating depression. The sucrose preference of the mouse is improved to a certain extent, the mood disorder is obviously reduced after the enterobacter murine is administered, and compared with fluoxetine, depression caused by chronic social contusion stress can be more quickly improved. The medicine is suitable for clinical popularization and use.

The application discloses a kind of for preventing or treating post myocardial infarction ventricular arrhythmia pharmaceutical composition, the pharmaceutical composition is by everolimus, ethmolam and fluoxetine, belongs to the field of medicine technology.Immunoblotting proves that everolimus, ethmolam and fluoxetine can inhibit fatty acid oxidation protein.In vitro and in vitro cardiac electrophysiology experiment proves that the pharmaceutical composition can effectively reduce post myocardial infarction ventricular arrhythmia susceptibility.TTC staining proves that the pharmaceutical composition can effectively reduce post myocardial infarction myocardial damage area.Based on the above composition in the regulation of post myocardial infarction ventricular arrhythmia susceptibility, it can be further developed in the clinical application of the disease.

The application discloses a kind of inhibitors of targeting 5-HTT / HDAC double target and preparation method and application thereof.The application is based on the principle of rational drug design, and synthesizes novel small-molecule compounds with 5-HTT and HDAC inhibitory activity, multi-targets with potential antidepressant activity.The inhibitors of targeting 5-HTT / HDAC double target have both 5-HTT inhibitor effect and HDAC inhibitory effect, and are a kind of multi-target fluoxetine derivatives with 5-HTT and HDAC synergistically realizing antidepressant.The compound of the application is superior to fluoxetine compound in design strategy, introduces isoxazoles structure that can improve antidepressant activity, improves antidepressant activity, and has good improvement on the shortcomings of long treatment time and large side effects of currently used antidepressant compounds.

The invention provides application of lactobacillus johnsonii YH1136 inactivated thalli in preparation of products for relieving depression, anxiety and sleep disorders, and relates to the technical field of microorganisms. The inactivated thallus is obtained by carrying out heat treatment on live thallus of lactobacillus johnsonii YH1136 with the preservation number of CCTCC NO: M 20221116 at 60 to 68 DEG C for 30 to 90 minutes. Animal experiments show that the inactivated thallus can significantly improve depression-like behaviors, anxiety-like behaviors and sleep disorders of CUMS model mice, and the effect of the inactivated thallus is equivalent to that of viable bacteria and positive drug fluoxetine, and is significantly superior to that of 100 DEG C traditional high-temperature inactivated thallus. The action mechanism is related to inhibition of HPA hyperfunction and up-regulation of hippocampal brain-derived neurotrophic factors and prefrontal cortex 5-hydroxytryptamine levels. The inactivated thallus provided by the invention is high in stability, good in safety and suitable for developing related drugs.

Galanin (1-15) and fluoxetine in the treatment of treatment-resistant depression, GAL (1-15) in combination with a seratonin reuptake inhibitor, preferably fluoxetine, for use in the treatment of treatment-resistant depression, and a composition comprising same.

The present invention describes pharmaceutical combinations of a 5HT3-antagonist, an NK1-antagonist and / or fluoxetine with pramipexole for the treatment of retinal degeneration, including Age-related Macular Degeneration. The present invention also describes methods for treatment of retinal degeneration, including Age-related Macular Degeneration by administration of the pharmaceutical combinations of the invention.

The invention belongs to the technical field of medicines, and particularly discloses a novel chalcone compound as well as a preparation method, a pharmaceutical composition and application thereof. The chalcone compounds (+)-lupulusone D and (-)-lupulusone D provided by the invention have not been reported at present. Experimental results show that the chalcone compounds (+)-lupulusone D and (-)-lupulusone D provided by the invention have a remarkable protection effect on corticosterone-induced SH-SY5Y cells, are obviously superior to a positive drug fluoxetine, and can be used for developing drugs for treating depression.

The invention relates to the technical field of medicines, and discloses diterpenoid alkaloid 3-acetyl aconitine as well as a pharmaceutical composition and application of the diterpenoid alkaloid 3-acetyl aconitine. The C19 type diterpenoid alkaloid 3-acetyl aconitine provided by the invention shows remarkable anti-depression activity in a mouse behavioral despair model experiment, is obviously superior to a positive drug fluoxetine, and can be used for developing anti-depression drugs.

The invention provides a compound preparation for treating erectile dysfunction and premature ejaculation and a preparation method thereof.The compound preparation contains a tadalafil inactive part and a fluoxetine hydrochloride active part, and the tadalafil inactive part contains a first stabilizer and a carrier; the tadalafil active part is used for preparing a solid dispersion from an active component tadalafil which is instable in absorption, and the particle size of the solid dispersion needs to be controlled; after the tadalafil active part is prepared into a solid dispersion, the solid dispersion, fluoxetine hydrochloride and auxiliary materials are prepared into a compound preparation, and the auxiliary materials comprise a filler, an adhesive, a disintegrating agent, a second stabilizer and a lubricant. The compound preparation provided by the invention can be used for treating erectile dysfunction and premature ejaculation at the same time. According to the compound preparation prepared by the preparation method provided by the invention, the problem of unstable absorption of tadalafil is reduced, the stability and dissolution rate of tadalafil are improved, the quality of the product is ensured, and the stability and safety of the product are improved.

The invention provides an application of selenium-rich probiotics in preparation of a preparation for treating fluoxetine-induced liver injury, and relates to the technical field of biological medicine, the application is characterized in that Se-BL is obtained by reducing sodium selenite through ascorbic acid and modifying the surface of bifidobacterium longum, and nano-scale selenium dots are formed. The preparation plays a role through dual mechanisms: active oxygen (ROS) is directly removed, an Nrf2 pathway is activated, and the liver oxidation resistance (GSH, SOD) is improved; the traditional Chinese medicine composition is capable of inhibiting NF-kappa B inflammation signal channels, reducing proinflammatory factors (TNF-alpha and IL-6) and synchronously regulating intestinal flora so as to enhance the intestinal barrier function. Experiments prove that the traditional Chinese medicine composition can remarkably reduce the level of serum transaminase (ALT / AST / ALP) and relieve liver tissue necrosis and lipid peroxidation damage (MDA), the dosage form of the traditional Chinese medicine composition is an oral preparation, and each dose of the traditional Chinese medicine composition contains 1 * 10 <-1 > * 10 <-1 > CFU of Se-BL viable bacteria. The selenium-modified probiotics are used for antagonizing hepatotoxicity of mental drugs for the first time, and an innovative therapy is provided for fluoxetine-induced drug-induced liver injury (DILI) and acute hepatic failure (ALF).

The invention discloses a pharmaceutical composition for preventing or treating ventricular arrhythmia after myocardial infarction, and belongs to the technical field of medicines. The pharmaceutical composition is prepared from everolimus, etomadectin and fluoxetine. Western blot proves that everolimus, etomadectin and fluoxetine can inhibit fatty acid oxidation protein. In-vitro and in-vitro cardiac electrophysiological experiments prove that the pharmaceutical composition can effectively reduce the ventricular arrhythmia susceptibility after myocardial infarction. TTC dyeing proves that the pharmaceutical composition can effectively reduce the myocardial injury area after myocardial infarction. Based on the regulation effect of the composition on the susceptibility of ventricular arrhythmia after myocardial infarction, the clinical application of the composition to the ventricular arrhythmia after myocardial infarction can be further developed.

The application provides a nano preparation for efficiently delivering neurotransmitters and a preparation method and application thereof, and the nano preparation is prepared from therapeutic drugs mon 5-hydroxytryptamine and catalase, a protein crown is formed by surface adsorption of human serum albumin, and a nano anti-depression preparation is constructed by connecting a targeting molecule neurotropic virus derived peptide. The surface modification of RVG29 can realize the crossing of the BBB, and the surface modification of HSA can effectively inhibit non-specific protein adsorption and improve the brain targeting efficiency of the nano particles. The nano anti-depression preparation releases 5- HT through weak acid induced degradation under a depressive microenvironment. The increase of 5- HT can universally improve depressive symptoms, and the problem of low response rate of fluoxetine nano delivery system is solved. The CAT in the nano preparation can significantly reduce neuroinflammation and improve depressive symptoms; meanwhile, the CAT can prevent 5- HT from being oxidized and inactivated by ROS in neuroinflammation, improve the curative effect of 5- HT, and multi-target combined treatment of depression, so that the problem of single target of anti-depression drugs is solved.

The invention discloses application of dihydroresveratrol in preparation of a medicine for treating depression, and belongs to the technical field of biological medicine. DHR or a pharmaceutically acceptable solvate thereof is taken as an active ingredient and can also be combined with fluoxetine for use, the use dosage of DHR is 1-100mg / kg, the use dosage of fluoxetine is 1-100mg / kg, and the dosage form is selected from at least one of tablets, capsules, granules, dripping pills, suspensions, syrups, enteric preparations, emulsion suspensions and injections. The invention also provides a pharmaceutical composition for treating depression. The pharmaceutical composition comprises DHR or a pharmaceutically acceptable solvate thereof. A chronic unpredictable mild stress mouse model verifies the effect of DHR in regulating neuroinflammation, oxidative stress, neuronal growth and the like, verifies that the effect of DHR in treating depression is better than that of fluoxetine used clinically, and has important clinical application value.

This invention belongs to the field of biomedical technology, specifically relating to a novel use of Yueju tablets in anxiolytic activity. Specifically, the Yueju tablets provided by this invention exhibited significant anxiolytic activity in a mouse acute anxiety model experiment, showing superior efficacy compared to the positive control drug fluoxetine in some models, and can be used to develop anxiolytic drugs. Preliminary mechanistic studies have shown that it exerts a significant anxiolytic effect by reducing neuroinflammation and protecting neuronal integrity.

The present invention provides a combination of a 5HT3-antagonist and / or a NK-1 antagonist with 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine and with fluoxetine or a pharmaceutically acceptable salt or solvate thereof, zonisamide or a pharmaceutically acceptable salt or solvate thereof, or a statin or a pharmaceutically acceptable salt or solvate thereof, for use for treating a protein misfolding neurodegenerative disease such as Alzheimer's disease, Lewy body disease, Parkinson's disease, or Huntington's disease.

The application discloses a use of an aporphine alkaloid shown in formula III in preparation of an antidepressant, wherein R1 and R2 are independently selected from alkoxy and methylenedioxy, R3 and R4 are independently selected from H, OH, alkoxy and methylenedioxy, but R3 and R4 cannot be H at the same time or R1 and R2 are both selected from methoxy, and R3 cannot be OH and R4 cannot be H. Pharmacological experiments show that the aporphine alkaloid shown in formula III has better antidepressant effect, higher response rate and faster effect than fluoxetine.

The present application relates to the low-toxicity and high-efficiency composition for preventing and treating depression, which can effectively solve the problem of preparing the low-toxicity and high-efficiency medicine for preventing and treating depression, and the composition is composed of rehmannia extract and fluoxetine, wherein the rehmannia extract is one of rehmannia water extract, rehmannia alcohol extract, rehmannia glycoside D and catalpol. The rehmannia water extract, rehmannia alcohol extract, catalpol and rehmannia glycoside D in rehmannia are selected for the first time, and are matched with fluoxetine to form the composition, so as to provide the safe and high-efficiency anti-depression composition, greatly improve the drug advantage, partially solve the hidden danger of liver toxicity of the current anti-depression drug to the clinical safe drug use, help to improve the compliance of the depression patients, maintain the body health of the depression patients, promote the recovery of the patients, improve the life quality of the patients, and have significant economic and social benefits.

The invention belongs to the technical field of medicines, and discloses a pharmaceutical composition for preventing or treating ventricular arrhythmia after myocardial ischemia-reperfusion, the pharmaceutical composition is composed of diosmin, etomoxazide and fluoxetine, and the mass ratio of diosmin to etomoxazide to fluoxetine is 1: 1: 1. Western blot proves that diosmin, etomagazide and fluoxetine can inhibit fatty acid oxidation protein. In-vitro and in-vitro heart electrophysiological experiments prove that the pharmaceutical composition can effectively reduce the susceptibility of ventricular arrhythmia after myocardial ischemia-reperfusion. TTC staining proves that the pharmaceutical composition can effectively reduce the myocardial injury area after myocardial ischemia reperfusion. Based on the regulation effect of the composition on the susceptibility of ventricular arrhythmia after myocardial ischemia-reperfusion, the clinical application of the composition to the ventricular arrhythmia after myocardial ischemia-reperfusion can be further developed.

The application belongs to the technical field of medicines, and specifically discloses a novel chalcone compound, a preparation method, a pharmaceutical composition and application thereof; the chalcone compounds (+)‑lupulusone D and (‑)‑lupulusone D provided by the application have not been reported so far. Experimental results show that the chalcone compounds (+)‑lupulusone D and (‑)‑lupulusone D provided by the application have a significant protective effect on SH‑SY5Y cells induced by corticosterone, and are obviously superior to a positive drug fluoxetine, and can be used for developing a drug for treating depression.

The invention relates to a preparation process of liposome simultaneously entrapping fluoxetine and celecoxib, and relates to the field of nano preparations. The preparation method comprises the following steps: forming a film from DOPG, cholesterol, DSPE-PEG2000, DSPE-PEG2000PGP, fluoxetine and celecoxib in a specific ratio by adopting chloroform, carrying out rotary evaporation in a water bath at 37 DEG C to volatilize a solvent, and hydrating PBS, so as to obtain the liposome preparation simultaneously entrapping two drugs.